Literature DB >> 20550529

Altered thyrotropic and lactotropic axes regulation in Huntington's disease.

N A Aziz1, Hanno Pijl, Marijke Frölich, Ferdinand Roelfsema, Raymund A C Roos.   

Abstract

BACKGROUND: Recently, a loss of hypothalamic dopamine D(2) receptors was demonstrated in Huntington's disease (HD). Activation of dopamine D(2) receptors is known to inhibit the function of both thyrotropic and lactotropic axes.
OBJECTIVE: To assess whether the activity of the thyrotropic and lactotropic axes is disturbed in patients with HD, contributing to symptoms such as unintended weight loss. PARTICIPANTS AND METHODS: In nine medication-free patients with early-stage HD (six men, three women) and nine age-, sex- and body mass index-matched controls, we measured serum levels of thyroid-stimulating hormone (TSH) and prolactin (men only) every 10 min for 24 h. Multiparameter auto-deconvolution and approximate entropy analysis were applied to quantify basal, pulsatile and total TSH and prolactin secretion rates as well as the regularity of hormone release.
RESULTS: Compared with controls, TSH and prolactin secretion tended to be slightly, but not significantly, higher in patients with HD (TSH: 1.13 ± 0.14 vs 0.91 ± 0.19 mU/l, P = 0.40; prolactin: 213 ± 18 vs 209 ± 11 pmol/l, P = 0.87). However, in patients with HD, total T(3) levels were significantly higher (1.60 ± 0.05 vs 1.35 ± 0.09, P = 0.045), while T(4) levels tended to be higher as well (91.9 ± 3.9 vs 81.3 ± 3.1, P = 0.085). Prolactin secretion was significantly more irregular in patients with HD (Approximate entropy (ApEn): 1.06 ± 0.08 vs 0.80 ± 0.09, P = 0.037). Total T(3) levels were negatively associated with motor impairment (r = -0.72, P = 0.030), whereas increasing free T(4) levels were associated with a larger mutant cytosine-adenine-guanine (CAG) repeat size (r = +0.68, P = 0.044).
CONCLUSION: Our findings indicate a mild hyperactivity of the thyrotropic axis and a disturbed regulation of the lactotropic axis in patients with early-stage HD.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20550529     DOI: 10.1111/j.1365-2265.2010.03836.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  6 in total

1.  Prolactin secretion in healthy adults is determined by gender, age and body mass index.

Authors:  Ferdinand Roelfsema; Hanno Pijl; Daniel M Keenan; Johannes D Veldhuis
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

2.  Loss of the thyroid hormone-binding protein Crym renders striatal neurons more vulnerable to mutant huntingtin in Huntington's disease.

Authors:  Laetitia Francelle; Laurie Galvan; Marie-Claude Gaillard; Martine Guillermier; Diane Houitte; Gilles Bonvento; Fanny Petit; Caroline Jan; Noëlle Dufour; Philippe Hantraye; Jean-Marc Elalouf; Michel De Chaldée; Nicole Déglon; Emmanuel Brouillet
Journal:  Hum Mol Genet       Date:  2014-11-14       Impact factor: 6.150

3.  A 24-Hour Study of the Hypothalamo-Pituitary Axes in Huntington's Disease.

Authors:  Eirini Kalliolia; Edina Silajdžić; Rajasree Nambron; Seán J Costelloe; Nicholas G Martin; Nathan R Hill; Chris Frost; Hilary C Watt; Peter Hindmarsh; Maria Björkqvist; Thomas T Warner
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240

4.  The Role of Hypothalamic Pathology for Non-Motor Features of Huntington's Disease.

Authors:  Rachel Y Cheong; Sanaz Gabery; Åsa Petersén
Journal:  J Huntingtons Dis       Date:  2019

5.  Factors Associated with Low Body Mass Index in Huntington's Disease: A Spanish Multicenter Study of the European Huntington's Disease Registry.

Authors:  Esther Cubo; Jessica Rivadeneyra; Natividad Mariscal; Asunción Martinez; Diana Armesto; Rafael J Camara
Journal:  Mov Disord Clin Pract       Date:  2016-01-18

Review 6.  A Critical Evaluation of Wet Biomarkers for Huntington's Disease: Current Status and Ways Forward.

Authors:  Edina Silajdžić; Maria Björkqvist
Journal:  J Huntingtons Dis       Date:  2018
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.